SCHEMBL308746

SCHEMBL308746

c1ccc(-c2cc(N(c3ccccc3)c3ccccc3)ccc2-c2ccc(N(c3ccccc3)c3ccccc3)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ATM Q13315 2/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
TLR9 Q9NR96 1/20 0.38
BACE1 P56817 1/20 0.38
ALOX5 P09917 1/20 0.38
APP P05067 1/20 0.37
PTGS2 P35354 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19433433 1.00 L3MBTL1 (0.45) L3MBTL1ALDH1A1MAPTKDM4ECYP1A2
SCHEMBL20558789 0.98 L3MBTL1 (0.43) L3MBTL1ALDH1A1MAPTKDM4ECYP1A2
SCHEMBL20484439 0.98 L3MBTL1 (0.43) L3MBTL1ALDH1A1MAPTKDM4ECYP1A2
SCHEMBL20620655 0.98 L3MBTL1 (0.43) L3MBTL1ALDH1A1MAPTKDM4ECYP1A2
SCHEMBL20484377 0.98 L3MBTL1 (0.43) L3MBTL1ALDH1A1MAPTKDM4ECYP1A2
SCHEMBL24079326 0.98 L3MBTL1 (0.43) L3MBTL1ALDH1A1MAPTKDM4ECYP1A2
SCHEMBL20620409 0.98 L3MBTL1 (0.43) L3MBTL1ALDH1A1MAPTKDM4ECYP1A2
SCHEMBL20582563 0.98 L3MBTL1 (0.43) L3MBTL1ALDH1A1MAPTKDM4ECYP1A2
SCHEMBL20620705 0.98 L3MBTL1 (0.43) L3MBTL1ALDH1A1MAPTKDM4ECYP1A2
SCHEMBL20620649 0.98 L3MBTL1 (0.43) L3MBTL1ALDH1A1MAPTKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2286474-A2 METHOD OF MAKING AN OLED Merck Patent GmbH (DE) 2011-02-23 EP claimed
WO-2009149860-A2 METHOD OF MAKING AN OLED MERCK PATENT GMBH (DE) 2009-12-17 WO claimed
EP-2011178-A2 ELECTROLUMINESCENT DEVICES INCLUDING ORGANIC ELECTRON INJECTION LAYER EASTMAN KODAK COMPANY (US) 2009-01-07 EP claimed
EP-1828342-B1 PHOSPHORESCENT OLEDS WITH EXCITON BLOCKING LAYER EASTMAN KODAK CO (US) 2008-12-31 EP claimed
WO-2007127063-A2 ELECTROLUMINESCENT DEVICES INCLUDING ORGANIC EIL LAYER EASTMAN KODAK COMPANY (US) 2007-11-08 WO claimed
US-20070252516-A1 Electroluminescent devices including organic EIL layer EASTMAN KODAK COMPANY 2007-11-01 US claimed
US-20060134461-A1 Organometallic materials and electroluminescent devices EASTMAN KODAK COMPANY 2006-06-22 US claimed
US-20060134460-A1 Phosphorescent oleds with exciton blocking layer GLOBAL OLED TECHNOLOGY LLC 2006-06-22 US claimed
EP-2984079-B1 HETEROCYCLIC COMPOUNDS AND THEIR USE IN ELECTRO-OPTICAL OR OPTO-ELECTRONIC DEVICES POWER OLEDS LTD (GB) 2020-07-01 EP disclosed
US-10439147-B2 Heterocyclic compounds and their use in electro-optical or opto-electronic devices POWER OLEDS LIMITED (GB) 2019-10-08 US disclosed
US-10281831-B2 Imaging members comprising capped structured organic film compositions XEROX CORPORATION (US) 2019-05-07 US disclosed
US-20180323378-A9 HETEROCYCLIC COMPOUNDS AND THEIR USE IN ELECTRO-OPTICAL OR OPTO-ELECTRONIC DEVICES POWER OLEDS LIMITED (GB) 2018-11-08 US disclosed
US-9921500-B2 Fluorinated structured organic film photoreceptor layers XEROX CORPORATION (US) 2018-03-20 US disclosed
EP-2232611-B1 BARRIER COATED SUBSTRATE AND ELECTRO-OPTICAL DEVICE MERCK PATENT GMBH (DE) 2017-11-01 EP disclosed
US-20060134461-A1 Organometallic materials and electroluminescent devices EASTMAN KODAK COMPANY 2006-06-22 US disclosed
US-20060134460-A1 Phosphorescent oleds with exciton blocking layer GLOBAL OLED TECHNOLOGY LLC 2006-06-22 US disclosed
EP-0805143-B1 ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC THIN FILM, AND TRIAMINE COMPOUNDS IDEMITSU KOSAN CO (JP) 2001-12-05 EP disclosed
US-6074734-A Organic electroluminescence device, organic thin film, and triamine compound IDEMITSU KOSAN CO., LTD. (JP) 2000-06-13 US disclosed
EP-0805143-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC THIN FILM, AND TRIAMINE COMPOUNDS IDEMITSU KOSAN COMPANY LIMITED (JP) 1997-11-05 EP disclosed
US-5466392-A Organic electroluminescence device and compound having an aluminum complex structure IDEMITSU KOSAN CO., LTD. (JP) 1995-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180323378-A9 HETEROCYCLIC COMPOUNDS AND THEIR USE IN ELECTRO-OPTICAL OR OPTO-ELECTRONIC DEVICES NAT1, SLCO2A1, SLCO2B1 L3MBTL1 899/4885ALDH1A1 789/4885MAPT 1775/4885
US-10439147-B2 Heterocyclic compounds and their use in electro-optical or opto-electronic devices NAT1, SLCO2A1, SLCO2B1 L3MBTL1 899/4885ALDH1A1 789/4885MAPT 1775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.